The top-ranked protein identified by CanSel was EMID2, which has the potential to make a significant impact in cancer therapy, as (i) it reduces tumor growth and dissemination in in vivo models of lung and pancreatic cancer, (ii) it modifies the composition of cancer ECM, reducing cell invasiveness, and (iii) its high expression levels are associated with good prognosis in aggressive human cancers. The gene discussed is COL26A1; the disease is pancreatic neoplasm.